Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Aminu Kano Teaching Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to investigate the effect of rebound exercise (mini trampoline jumping) on metabolic outcomes and quality of life in patients with Type 2 Diabetes.
The exercise involved jumping on the mini trampoline with feet slightly apart. Participants stood on the mid portion of the trampoline bed and made repeated up-and-down bouncy movements. Each foot strike equals one step or bounce. With each landing, the mat of the trampoline underwent deformation and the springs released the energy stored in them such that the participant was made to bounce off the mat. Exercise was administered for between 10 - 15 minutes after which a 5-minute period of rest was allowed. A heart rate monitor was used to guide the intensity of the exercise in the moderate range. Each participant accumulated between 20 and 30 minutes of rebound exercise (bouncing on a mini trampoline) per session, administered three times per week for 12 weeks. All data were captured at baseline and at the end of the 12-week intervention period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Rebound exercise | Experimental | Repeated jumping on a mini trampoline was performed with feet slightly apart |
|
| Control | No Intervention | No exercise was administered but participants continued with routine medical care |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rebound exercise | Other | Repeated jumping on a mini trampoline was administered |
|
| Measure | Description | Time Frame |
|---|---|---|
| Glycated hemoglobin | Glycated hemoglobin was assessed using the mini-column ion-exchange chromatographic method and expressed in percentage | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Fasting plasma glucose | Fasting plasma glucose (in molar concentration) was measured by glucose oxidase assay using a glucose analyzer | 3 months |
| Fasting insulin | Fasting insulin (in gravimetric unit) was determined using a commercially available ELISA human insulin kit |
| Measure | Description | Time Frame |
|---|---|---|
| Depressive symptoms as measured by the Beck's Depression Inventory | Score ranges from 0 to 63 with 0 to 13 being minimal and 29 to 63 being severe | 3 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sonill S Maharaj, PhD | UKZN | Study Chair |
Not provided
Data would not be shared
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 months |
| High-density lipoprotein cholesterol | High-density lipoprotein cholesterol (in molar concentration) was enzymatically determined using commercial kits | 3 months |
| Total cholesterol | Total cholesterol (in molar concentration) was enzymatically determined using commercial kits | 3 months |
| Triglycerides | Triglycerides (in molar concentration) were enzymatically determined using commercial kits | 3 months |
| Low-density lipoprotein cholesterol | Low-density lipoprotein cholesterol (in molar concentration) was estimated using the Friedewald formula. | 3 months |
| Quality of life | The short-form 36 health questionnaire was used to assess participants' quality of life and expressed in percentage | 3 months |
| Body mass | Body mass in kilograms was determined using a calibrated weighing scale | 3 months |
| Height | Height in meters was determined using a stadiometer | 3 months |
| Heart rate | Heart rate was measured in beats per minute using a calibrated electronic device | 3 months |
| Respiratory rate | Respiratory rate (in cycles per minute) was measured by observing and counting the number of times the chest rose in one minute | 3 months |
| Blood pressure | Blood pressure in millimeters of mercury (mmHg) was measured using a calibrated electronic device | 3 months |
| Maximal oxygen consumption | Maximal oxygen consumption in milliliters per kilogram per minute (ml/kg/min) was obtained from exercise stress testing | 3 months |
| Diabetes-related emotional distress as measured by the Problem Areas in Diabetes Scale | Diabetes-related emotional distress was expressed in percentage | 3 months |
| Well-Being as measured by the World Health Organization-Well-Being Index | Participants' well-being was expressed in percentage | 3 months |
| Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire | Score ranges from 0 (very dissatisfied) to 36 (very satisfied) | 3 months |
| D004700 | Endocrine System Diseases |